Drugs / iseganan
iseganan
also known as
IB-367 · IB-367-03 · ISEGANAN HYDROCHLORIDE · Iseganan hydrochloride anhydrous · Iseganan hydrochloride hydrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00118781 | Sep 2003 → Jun 2004 | pneumonia | IntraBiotics Pharmaceuticals | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00022373 | Dec 2000 → ? | head and neck cancer, radiation-induced disorder, stomatitis | National Cancer Institute (NCI) | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iseganan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00118781 ↗ |
| Known as | IB-367 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110753 ↗ |
| Known as | IB-367-03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110753 ↗ |
| Known as | ISEGANAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110753 ↗ |
| Known as | Iseganan hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110753 ↗ |
| Known as | Iseganan hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110753 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2110753 ↗ |
| Route | Oral | “Patients rinse with iseganan HCl oral solution 6 times daily.” NCT00022373 ↗ |